In Praise of Senator Ted Kennedy For His Contributions to Biomedical Science
Earlier this month, I had the tremendous honor of being asked to discuss Senator Ted Kennedy’s remarkable contributions to biomedical science at an event celebrating The Edward M. Kennedy Institute for the United States Senate that was organized by The Massachusetts healthcare and life sciences communities. Following are my comments:
As I studied the record of the Senator, it became apparent that few national leaders have had as significant impact on the current state of biomedical science and healthcare delivery. He has been foresighted in his leadership by championing inclusion of the disadvantaged into the healthcare system and at the same time strengthening biomedical research that advances the range and quality of treatments available.
Senator Kennedy was first elected to the Senate 46 years ago in 1962. Relating this tenure to my own experiences in science, he was a Senator when I graduated from high school and has shaped many of the opportunities in my life, even though at the time I was unaware of it.
The center of biomedical research and innovation in healthcare in the world is now in Massachusetts. This epicenter has grown over the 40 years of Senator Kennedy’s tenure and will create a large part of the future of healthcare. The foundations of this epicenter, with the addition of biotechnology in the 70s, were the universities such as Harvard, MIT, BU, Tufts, BC, and others—and the great hospitals such as MGH, Brigham and Women’s, Dana Farber Cancer Institute, Children’s Hospital, and many others.
Senator Kennedy’s leadership in encouraging advances in biomedical research began with his election as Chairman of the Senate Health Subcommittee in 1971. In this capacity, he helped pass the National Cancer Act that established the modern National Cancer Institute and quadrupled the funds supporting cancer research. Senator Kennedy stated his support of biomedical research at the time as: “The conquest of cancer is a special problem of such enormous concern to all Americans.” In relating his feelings to those of the country, he further stated, “We can quote statistics. But I think every one of us in this body, and most families across the country have been touched by the disease one way or another.” I am sorry to say that this has certainly been the case for the Senator’s family.
The National Cancer Act has been important for biomedical research across the country and particularly here in Boston. It greatly strengthened the already-strong cancer research and treatment programs at the Dana Farber, MGH, and Children’s Hospital. In addition, this act radically changed the course of research in life sciences at MIT. For example, Professor Salvador Luria, subsequently a Nobel Laureate, convinced MIT to support his application to NCI for funds to establish a new center dedicated to research into fundamental aspects of cancer. David Baltimore took leadership in recruiting the staff of the center; this included yours truly, who joined MIT in 1974.
Research from the Center has been important in the development of several highly successful new targeted therapies. Perhaps more important in terms of the region, the success of MIT’s Center for Cancer Research either directly or indirectly led to the establishment of the Whitehead Institute, the Broad Institute, and the Koch Institute. These institutes, along with MGH and Harvard, have shaped the Kendall Square area with a large concentration of biotechnology companies. There are similar stories about the importance of the National Cancer Act at other universities and hospitals in Massachusetts. This act passed with Senator Kennedy’s leadership clearly initiated a revolution in cancer research and treatment across the country.
Funds for cancer research have grown over the intervening years with Senator Kennedy’s support ,and we pray that he will benefit from these advances in his current struggle. Although no one is satisfied with current treatments of cancer, significant progress has been made. The rate of age-dependent death due to cancer has fallen over the past decade by 25 percent. There are more promising new drugs and treatments under development now than at any time in history. We are making significant … Next Page »